Pacific Biosciences of California Inc expected to post a loss of 13 cents a share - Earnings Preview

Pacific Biosciences of California

03/08/2026 23:14

Pacific Biosciences of California Inc PACB.OQ PACB.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 for the period ending June 30 2026
The Menlo Park California-based  company is expected to report a 0.8% increase in revenue to $40.067 million from $39.77 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Pacific Biosciences of California Inc is for a loss of 13 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $2.63, about 87.5% above its last closing price of $1.40
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.14
-0.13
-0.12
Beat
11
Dec. 31 2026
-0.12
-0.15
-0.12
Beat
18.6
Sep. 30 2025
-0.12
-0.15
-0.13
Beat
14.5​
Jun. 30 2025
-0.17
-0.17
-0.14
Beat
17.6
​​Mar. 31 2025
-0.19
-0.19
-1.44
Missed
-661.9
Dec. 31 2024
-0.21
-0.21
-0.49
Missed
-138.6​
Sep. 30 2024
-0.24
-0.22
-0.22
Met
2
Jun. 30 2024
-0.24
-0.23
-0.64
Missed
-175.1
This summary was machine generated August 3 at 22:14 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)